Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral Healthmhn dTMS OCD Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.BH.201

    Deep Transcranial Magnetic Stimulation for the Treatment of Obsessive Compulsive Disorder

    Customize your policy alerts

    Sign up for mhn Policy CP.BH.201 alerts

    Get alerted when Policy CP.BH.201 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria, coding, and coverage stance for use of deep transcranial magnetic stimulation to treat obsessive-compulsive disorder for members/enrollees of the payer.

    Policy Summary
    Payermhn
    PolicyDeep Transcranial Magnetic Stimulation for the Treatment of Obsessive Compulsive Disorder
    Policy CodePolicy CP.BH.201
    Change TypeMaterial clinical revisions and coding updates
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization demonstrating age ≥18, DSM-confirmed OCD, required failed trials of CBT/ERP and four medication trials, and request limited to up to 36 sessions using an FDA-cleared device.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Changed the allowed initial number of sessions from 30 to up to 36 sessions (recommended 5 days/week for 6 weeks with optional six taper sessions).

    Updated contraindication list by removing several relative contraindications (history of seizures, severe dementia, severe cardiovascular disease, active suicidal ideation with intent) and replacing other items (e.g., substance use remission requirement).

    Clarified medication failure criteria to require lack of clinically significant response to four trials from at least two agent classes, with at least two SSRI/SNRI/clomipramine or atypical antipsychotic trials of >=12 weeks.

    Specified FDA-cleared devices acceptable for treatment (examples listed).

    Changed response thresholds and retreatment response criteria from 25%/50% reductions to 30% reductions in some sections.

    Request is for up to 36 sessions (Recommended schedule is for five days a week for six weeks, with an optional six sessions for tapering).

    Removed certain relative contraindications (history of seizures, severe dementia, severe cardiovascular disease, active suicidal ideation with intent) and removed 'pregnancy' and 'neurological disease or head injury' from the contraindication list.

    New CPT/HCPCS codes added: 97014 and 97032 for electrical stimulation modalities.

    36maximum approved sessions (initial course)
    30%response threshold
    4required failed medication trials
    Y-BOCSseverity scale
    2new billing codes

    Coverage and Medical Necessity Criteria

    Initial Therapy

    Covered when ALL of the following are met for initial treatment:

    Initial dTMS coverage criteria: A. The member/enrollee is ≥ 18 years old; B. The member/enrollee has a confirmed diagnosis of obsessive-compulsive disorder (OCD) per the current DSM; C. OCD is not part of a presentation with multiple psychiatric comorbidities; D. The member/enrollee failed to respond to a combination of multiple trials of medication combined with Cognitive Behavioral Therapy (CBT) and/or Exposure and Response Prevention (ERP) for at least 12 weeks during the current episode, as demonstrated by both: (1) less than 25% improvement in the Yale Brown Obsessive Compulsive Scale (Y-BOCS); (2) failure to respond to four trials of psychopharmacologic agents representing at least two different agent classes, with at least two trials administered as adequate mono- or poly-drug therapy using SSRIs, SNRIs, clomipramine, or atypical antipsychotic augmentation at standard therapeutic doses for ≥12 weeks, OR documented inability to take these agents due to drug interactions or intolerability as evidenced by trials of four agents with distinct side effects; E. Request is for up to 36 sessions (recommended schedule: five days per week for six weeks, with an optional six taper sessions); F. Treatment is administered using an FDA-cleared device and coil used in accordance with labeled indications (examples include Brainsway dTMS H7 coil, MagVenture cool DB80 coil, Magstim Horizon 3.0 with E‑z Cool Coil, NeuroStar Advanced Therapy System); G. Direct supervision of treatment is provided by a licensed psychiatrist except where state scope of practice allows other provider types to supervise; H. No contraindications present, including but not limited to: conductive or ferromagnetic metals implanted or embedded in the head/neck within 30 cm of coil placement (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips/coils, stents, bullet fragments, metallic tattoo ink, vagus nerve stimulators), other implanted stimulators (e.g., deep brain stimulation, cardiac pacemaker, cardioverter defibrillator, intracardiac lines, medication pumps), less than three months of substantiated remission from a substance use disorder, known non-adherence to prior OCD treatment, or presence of any mental health disorder other than OCD.

    Maintenance Therapy

    Maintenance therapy:

    Maintenance dTMS: Maintenance treatment with dTMS for obsessive-compulsive disorder is considered not medically necessary due to insufficient peer-reviewed literature to support maintenance treatment at this time.

    Retreatment

    Retreatment (case-by-case review):

    Retreatment criteria: Retreatment with dTMS will be reviewed on a case-by-case basis by a medical director and requires all of the following: A. Criteria for initial dTMS treatment continue to be met; B. Current OCD symptoms have worsened with Y-BOCS scores > 15; C. Prior treatment response was at least a 30% reduction from baseline OCD scores with a documented 6-month duration of response.

    Requests for retreatment are subject to individual medical director review and documentation requirements.

    Coverage with criteria

    Covered when criteria in the policy are met; notable operational criteria and limits updated during review.

    Primary coverage rules: Policy allows coverage of deep TMS for OCD when the detailed clinical criteria in this policy are fulfilled. Operational updates during the review included increasing the allowed initial number of sessions to up to 36 (recommended schedule: 5 days/week × 6 weeks with optional taper), reworking and consolidating contraindication language (e.g., removing certain prior relative contraindications and updating substance use remission requirement to ≥3 months), and adding CPT/HCPCS codes for billing.

    See initial, maintenance, and retreatment sections for full clinical criteria and specific contraindications; prior authorization and documentation requirements apply.

    Explicit exclusions include members with conductive or ferromagnetic or other magnetic‑sensitive metals implanted or embedded in the head or neck within 30 cm of the dTMS H7 coil placement (other than dental fillings). Examples called out in the policy include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, metallic tattoo dyes, and vagus nerve stimulators. The policy also excludes members with other implanted stimulators that are controlled by or use electrical or magnetic signals (for example: deep brain stimulation systems, cardiac pacemakers, cardioverter defibrillators, intracardiac lines, medication pumps).

    The contraindication list was revised to consolidate and remove several prior relative contraindications. Notable changes include removal of prior items such as history of seizures, severe dementia, severe cardiovascular disease, and active suicidal ideation with intent. The policy language was also clarified regarding supervision and wording for substance‑use remission, and redundant items were combined where appropriate.

    Maintenance dTMS for obsessive‑compulsive disorder is considered not medically necessary because the policy finds there is insufficient peer‑reviewed literature to support routine maintenance treatment with dTMS at this time.

    During the policy update, the following previously listed items were removed from the contraindication list: pregnancy and neurological disease or head injury. In addition, the policy clarified the substance‑use criterion to require less than three months of substantiated remission from a substance use disorder as a contraindication, and removed other relative contraindications as noted above.

    Coding and Severity Definitions

    Referenced CPT/HCPCS Codesmixed
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery, and management.
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session.
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management.
    97014Application of a modality to 1 or more areas; electrical stimulation (unattended).
    97032Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes.
    Added CPT/HCPCS codesCPT
    97014Application of a modality to 1 or more areas; electrical stimulation (unattended)
    97032Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes
    Y-BOCS severity thresholds
    SubclinicalY-BOCS total score < 8
    MildY-BOCS total score 8 - 15
    ModerateY-BOCS total score 16 - 23
    SevereY-BOCS total score 24 - 31
    ExtremeY-BOCS total score 32 - 40
    Maximum approved sessions — initial course
    Initial course maximumUp to 36 sessions per initial course

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required: age, DSM diagnosis, failed trials, and contraindications

    Prior authorization is required for dTMS for OCD and must document the member is ≥18 years old, a DSM-confirmed diagnosis of OCD, failure of the required medication and CBT/ERP trials, and absence of listed contraindications. The request must also identify the planned FDA‑cleared device and coil.

    • Member is ≥ 18 years old (I.A)
    • Confirmed DSM diagnosis of OCD (I.B)
    • Failed combination of multiple medication trials plus CBT and/or ERP for ≥12 weeks during current episode (I.D)
    • No contraindications present (I.H)
    • Planned use of an FDA‑cleared device/coil (I.F)
    Prior Authorization

    Prior authorization requests: session count and recommended schedule

    Submit prior authorization for up to 36 sessions; include the recommended treatment schedule (five days per week for six weeks) and note optional six taper sessions when applicable. Requests should be limited to the specified session count.

    Background and Clinical Context

    Obsessive‑compulsive disorder (OCD) is characterized by intrusive obsessions and repetitive compulsions that impair functioning. First‑line treatments include evidence‑based psychotherapy—particularly cognitive‑behavioral therapy with exposure and response prevention (CBT/ERP)—and serotonin‑reuptake pharmacotherapy (SSRIs/SNRIs) or clomipramine, often with augmentation strategies when indicated. Per the policy, dTMS is positioned as a later‑line option for adults (age ≥18) with a confirmed DSM diagnosis of OCD who have not achieved an adequate response to recommended first‑line therapies: inadequate clinical response after four pharmacologic trials representing at least two different agent classes (with at least two SSRI/SNRI/clomipramine or atypical antipsychotic augmentation trials of ≥12 weeks), and an adequate trial of CBT/ERP. dTMS treatment is specified to use an FDA‑cleared device and is limited to an initial request of up to 36 sessions (recommended 5 days/week for 6 weeks with an optional six‑session taper).

    Definitions and Measurement Tools

    Y-BOCS definition
    ScaleYale-Brown Obsessive Compulsive Scale (Y-BOCS), a standardized clinician-rated 10-item scale
    Item scoringEach item scored 0 (no symptoms) to 4 (extreme symptoms)
    Total score rangeTotal score range 0 to 40
    dTMS definition
    DefinitionDeep Transcranial Magnetic Stimulation (dTMS) is a non‑invasive magnetic stimulation technique using an H‑7 coil to stimulate deeper brain regions including the anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC)
    Device/coils referencedExamples: Brainsway dTMS H7 coil, MagVenture (cool DB80) coil, Magstim Horizon 3.0 with E‑z Cool Coil, NeuroStar Advanced Therapy System

    Treatment Modalities and Device Information

    TMS/dTMS

    dTMS modality: dTMS uses an H‑7 coil or other FDA‑cleared coils to stimulate medial prefrontal cortex and anterior cingulate cortex; sessions are typically delivered daily and may include individualized symptom provocation as used in pivotal trials.

    Examples of FDA‑cleared devices and coils are listed in the policy (e.g., Brainsway H7, MagVenture cool DB80, Magstim Horizon 3.0, NeuroStar).

    TMS

    TMS modality context: Conventional TMS (including figure‑8 coils and H‑coils) is described as a noninvasive neuromodulation technique that delivers magnetic pulses via a generator coil to modulate brain activity; the Clinical TMS Society and guideline sources are referenced regarding TMS as an add‑on for patients who have tried first‑line treatments such as ERP and pharmacotherapy.

    Device clearances and key trials are cited in the policy references.

    Session Limits and Visit Frequency

    dTMS treatment sessions
    Session limit (initial course)Up to 36 sessions per initial course
    Typical scheduleFive sessions per week for six weeks
    Optional taperOptional six taper sessions as part of the course
    dTMS sessions — summary
    Numeric session limit (summary)36 total sessions per treatment course (including optional taper)
    Recommended durationApproximately 6 weeks of daily weekday treatments
    Authorization requirement
    Policy Summary
    Payermhn
    PolicyDeep Transcranial Magnetic Stimulation for the Treatment of Obsessive Compulsive Disorder
    Policy CodePolicy CP.BH.201
    Change TypeMaterial clinical revisions and coding updates
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization demonstrating age ≥18, DSM-confirmed OCD, required failed trials of CBT/ERP and four medication trials, and request limited to up to 36 sessions using an FDA-cleared device.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Severity DefinitionsProvider Requirements, Prior Authorization, and DocumentationBackground and Clinical ContextDefinitions and Measurement ToolsTreatment Modalities and Device InformationSession Limits and Visit Frequency
    Recommended primary scheduleFive days per week for six weeks
    Optional tapering sessionsOptional six additional taper sessions (included in the up to 36 count)
    Prior authorization noteRequests for the initial course must request up to 36 sessions and include required documentation
    • Request is for up to 36 sessions (I.E)
    • Recommended schedule: five days/week × 6 weeks with optional 6 taper sessions (I.E; chunk 18)
    Step Therapy

    dTMS reserved for members who failed first‑line CBT/ERP and pharmacotherapy

    dTMS is reserved for members who have failed first‑line treatments. Providers must document adequate CBT/ERP and required pharmacotherapy trials per the policy before authorization will be approved.

    • Failed combination of multiple medication trials plus CBT and/or ERP for at least 12 weeks during the current episode (I.D)
    • TMS is an add‑on after trials of ERP and/or medication per guideline recommendations (International OCD Foundation)
    Note

    Provider responsibilities: supervision and device use

    Include any remaining provider‑action specifics recorded in the policy (e.g., supervision and device requirements). Direct supervision must be provided by a licensed psychiatrist unless state scope of practice allows other providers to supervise.

    • Direct supervision of treatment by a licensed psychiatrist unless state scope allows otherwise (I.G)
    • Treatment administered using an FDA‑cleared device in accordance with labeled indications (I.F)
    Documentation Required

    Required documentation: diagnosis, Y‑BOCS, prior therapy records, and device

    Documentation must include a DSM‑confirmed OCD diagnosis, baseline and follow‑up Y‑BOCS scores, and detailed records of prior CBT/ERP and pharmacologic trials (including agents, classes, durations, and reasons for failure or intolerance). Also document the FDA‑cleared device and coil used.

    • DSM‑confirmed OCD diagnosis (I.B)
    • Baseline and response Y‑BOCS scores (I.D.1; Y‑BOCS description)
    • Records of prior CBT/ERP and pharmacologic trials, including four trials from ≥2 classes and durations (I.D.2)
    • Device used (FDA‑cleared device/coil) (I.F)
    Documentation Required

    Document response duration (6 months) for retreatment

    For continuation or retreatment considerations, provide documentation of prior treatment response durability — specifically a documented 6‑month duration of response where applicable. This supports retreatment decisions per policy.

    • Retreatment requires prior response of at least 30% drop from baseline with a documented 6‑month duration (III.C)
    • Policy references documented 6‑month duration of response in background/retreatment context
    Denial Risk

    Denial risks: common reasons requests may be denied

    Requests may be denied for specific reasons: member age <18, lack of a confirmed DSM diagnosis of OCD, insufficient prior treatments (no adequate CBT/ERP or required medication trials), presence of significant comorbid psychiatric disorders, or listed contraindications (e.g., metal implants, other implanted stimulators, <3 months remission from substance use disorder, known non‑adherence).

    • Member is under 18 (I.A)
    • No confirmed DSM diagnosis of OCD (I.B)
    • Insufficient prior treatment: did not fail required medication + CBT/ERP trials for ≥12 weeks (I.D)
    • Presence of other mental health disorders (I.H.5)
    • Contraindications such as conductive/ferromagnetic implants or other implanted stimulators, less than 3 months remission from substance use disorder, known non‑adherence (I.H.1–4)
    Billing Rule

    Session limit enforcement: up to 36 sessions and schedule adherence

    Requests that exceed the approved session limit (policy allows up to 36 sessions for the initial course) or that do not follow the recommended schedule (five days/week × 6 weeks with optional taper) may be denied. Ensure authorization requests and clinical documentation match the session count and schedule.

    • Policy allows up to 36 sessions for the initial course (I.E)
    • Recommended schedule: five days/week for six weeks with optional six taper sessions (I.E)
    • Requests exceeding the approved number of sessions or not following recommended schedule may trigger denial (denial risks/module language)
    MechanismUses magnetic fields to modulate neural activity of brain structures associated with OCD
    Supporting evidence
    Randomized controlled trialCarmi et al., Am J Psychiatry 2019: Prospective multicenter randomized double‑blind placebo‑controlled trial showing efficacy and safety of dTMS for OCD (Carmi L et al.)
    Real‑world evidenceRoth et al., J Psychiatr Res. 2021: Post‑marketing real‑world efficacy data collected from 22 clinical sites
    FDA device clearancesFDA clearances cited: Brainsway (K183303), Magstim (K222171), MagVenture (K221544), NeuroStar (K212289)
    Systematic review/HTAGrassi et al. 2023 systematic review and Hayes Health Technology Assessment referenced in bibliography
    Prior authorization required for requests up to the 36‑session limit